BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Hanadi Qashqari, Amany Al-Mars, Adeel Chaudhary, Adel Abuzenadah, Ghazi Damanhouri, Mohammed Alqahtani, Maged Mahmoud, Maysaa El Sayed Zaki, Kaneez Fatima, Ishtiaq Qadri. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistanceInfection, Genetics and Evolution 2013; 19: 113 doi: 10.1016/j.meegid.2013.06.025
2
Biotechnology in Medical Sciences2014; : 131 doi: 10.1201/b16905-7
3
Masoud Keikha, Majid Eslami, Bahman Yousefi, Mohammad Ali-Hassanzadeh, Ali Kamali, Masoud Yousefi, Mohsen Karbalaei. HCV genotypes and their determinative role in hepatitis C treatmentVirusDisease 2020;  doi: 10.1007/s13337-020-00592-0
4
Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, PakistanAsian Pacific Journal of Tropical Biomedicine 2012; 2(7): 532 doi: 10.1016/S2221-1691(12)60091-4
5
W.M.S. Degrave, L. Mendonça-Lima. Current Developments in Biotechnology and Bioengineering2017; : 51 doi: 10.1016/B978-0-444-63660-7.00003-6
6
Jing-Hong Hu, Ming-Ling Chang, Tung-Jung Huang, Chau-Ting Yeh, Wen-Nan Chiu, Ming-Shih Chiang, Mei-Yen Chen. Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis CJournal of Interferon & Cytokine Research 2019; 39(4): 205 doi: 10.1089/jir.2018.0028
7
Yan Guan, Huiyong Sun, Youyong Li, Peichen Pan, Dan Li, Tingjun Hou. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: A general mechanism of drug resistanceAntiviral Research 2014; 103: 60 doi: 10.1016/j.antiviral.2014.01.010
8
Mortada El-Shabrawi, Mona Isa. Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical PracticeHepatitis Monthly 2013; 13(2) doi: 10.5812/hepatmon.7867